← Back to Browse

Evolus, Inc.

EOLS • Healthcare

Compare

About Evolus, Inc.

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc.

Current Price
$6.61
Market Cap
$397M

Quality Assessment

Evolus, Inc. is a below-average quality healthcare company with a Compass Score of 36. Weak fundamentals or high volatility. More of a speculative position than a core holding.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Fair Value

Pro

See whether this stock trades above or below its fair value.

Wall Street View

Consensus
Hold
Analysts
7
Price Target
๐Ÿ”’
Upside
๐Ÿ”’

Catalyst Signal

Plus

Recent earnings beats and analyst-upgrade momentum. How it works

Catalyst Score
๐Ÿ”’
EPS Beat Streak
๐Ÿ”’
Net Upgrades (180d)
๐Ÿ”’

See recent earnings beats and analyst-upgrade momentum.

Analyst Track Record

Plus

See each covering analyst's historical hit rate.

Financial Health

Plus

Click any metric for details

See bankruptcy-risk and financial-strength scores for this company.

Growth Projections

Plus
Projected EPS Growth
๐Ÿ”’
Projected Revenue Growth
๐Ÿ”’

See projected EPS and revenue growth for this company.

Technical Overview

Click any metric for details

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.